25,400 Shares in Supernus Pharmaceuticals, Inc. $SUPN Bought by Mystic Asset Management Inc.

Mystic Asset Management Inc. acquired a new stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 25,400 shares of the specialty pharmaceutical company’s stock, valued at approximately $1,181,000.

Several other hedge funds also recently made changes to their positions in SUPN. Bank of America Corp DE grew its holdings in shares of Supernus Pharmaceuticals by 37.2% during the first quarter. Bank of America Corp DE now owns 714,226 shares of the specialty pharmaceutical company’s stock worth $36,918,000 after buying an additional 193,479 shares during the last quarter. Rice Hall James & Associates LLC purchased a new stake in Supernus Pharmaceuticals during the 2nd quarter valued at approximately $22,800,000. Westover Capital Advisors LLC purchased a new stake in Supernus Pharmaceuticals during the 4th quarter valued at approximately $1,587,000. Stephens Investment Management Group LLC lifted its position in Supernus Pharmaceuticals by 4.5% during the 4th quarter. Stephens Investment Management Group LLC now owns 1,406,522 shares of the specialty pharmaceutical company’s stock worth $69,904,000 after acquiring an additional 61,120 shares during the period. Finally, Elmind Capital LP purchased a new position in Supernus Pharmaceuticals in the 4th quarter valued at $994,000.

Supernus Pharmaceuticals Trading Down 2.2%

Shares of Supernus Pharmaceuticals stock opened at $47.45 on Friday. Supernus Pharmaceuticals, Inc. has a 12-month low of $42.45 and a 12-month high of $59.68. The stock has a market cap of $2.76 billion, a PE ratio of -24.71, a price-to-earnings-growth ratio of 0.89 and a beta of 0.56. The company has a 50-day moving average of $46.72 and a two-hundred day moving average of $48.85.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its quarterly earnings results on Monday, August 3rd. The specialty pharmaceutical company reported ($1.01) earnings per share for the quarter, missing analysts’ consensus estimates of $0.42 by ($1.43). Supernus Pharmaceuticals had a positive return on equity of 11.13% and a negative net margin of 13.23%.The firm had revenue of $219.06 million during the quarter, compared to analyst estimates of $205.31 million. During the same quarter in the prior year, the company earned $0.40 EPS. The business’s revenue was up 32.4% on a year-over-year basis. On average, sell-side analysts forecast that Supernus Pharmaceuticals, Inc. will post 1.97 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on SUPN. Wall Street Zen lowered shares of Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Zacks Research upgraded shares of Supernus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Thursday, August 6th. Weiss Ratings restated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research note on Wednesday, June 24th. Finally, Cantor Fitzgerald increased their price objective on Supernus Pharmaceuticals from $63.00 to $67.00 and gave the stock an “overweight” rating in a research report on Thursday, July 9th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $62.83.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained?release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended?release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended?release capsules), approved for the treatment of attention?deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.